2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

Lymphoma cell lines

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

1

Peptides

2

Inhibitory Antibodies

2

Natural
Products

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148026
    Sonrotoclax

    BGB 11417

    		 Bcl-2 Family Cancer
    Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines .
    Sonrotoclax
  • HY-160698
    SGR-1505

    		MALT1 Inflammation/Immunology Cancer
    SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proliferative activity in BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 can be used for research of B-cell lymphomas .
    SGR-1505
  • HY-149221
    Apoptosis inducer 11

    		Apoptosis Cancer
    Apoptosis inducer 11 (compound 3u) induces apoptosis through the mitochondrial pathway. Apoptosis inducer 11 induces a block in G2/M, a strong decrease in S phase in non-Hodgkin lymphoma cell lines .
    Apoptosis inducer 11
  • HY-116708
    DCE_254

    		Histone Methyltransferase Cancer
    DCE_254 is an EZH2 inhibitor (IC50=11 μM) that also exhibits significant antiproliferative activity against lymphoma cell lines. DCE_254 inhibits the development of hypermethylation-related cancers by inhibiting the SAM-mediated methyl transfer process (IC50=10.3 μM) .
    DCE_254
  • HY-137200
    N-Desmethyl Bendamustine

    		Drug Metabolite Cancer
    N-Desmethyl Bendamustine is a metabolite of Bendamustine (HY-13567). N-Desmethyl Bendamustine has cytotoxic effect in several lymphoma cell lines and peripheral blood lymphocytes .
    N-Desmethyl Bendamustine
  • HY-153320
    AZ-TAK1

    		MAP3K Cancer
    AZ-TAK1, an ATP-competitive small molecule inhibitor of TAK1, dephosphorylates TAK1, p38, and IκB-α in lymphoma cell lines .
    AZ-TAK1
  • HY-122829
    BCL6 PROTAC 1

    		PROTACs BCL6 Cancer
    BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) PROTAC. BCL6 PROTAC 1 inhibits BCL6 cell reporter with an IC50 value of 8.8 µM. BCL6 PROTAC 1 significantly degrades BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6 PROTAC 1 can be used in tumor related research .
    BCL6 PROTAC 1
  • HY-111537
    rel-AZ5576

    		c-Myc CDK Bcl-2 Family Others
    rel-AZ5576 is a selective CDK9 inhibitor with the activity of downregulating Mcl-1 and MYC mRNA transcription and protein expression in diffuse large B-cell lymphoma by inhibiting CDK9, promoting MYC protein turnover, reducing MYC phosphorylation on the stable Ser62 residue and downregulating MYC transcriptional targets, inhibiting the growth of diffuse large B-cell lymphoma cell lines in vitro and in vivo and independent of the cell origin.
    rel-AZ5576
  • HY-155557
    Anti-inflammatory agent 45

    		Apoptosis Cancer
    Anti-inflammatory agent 45 (compound 2v) is an anticancer agent with direct inhibitory effects on the growth of different blood cancers including leukemia, lymphoma and myeloma cell lines. Anti-inflammatory agent 45 induces apoptosis and inhibits NO production in HL60 leukemia cells (IC50=14.7 μM) .
    Anti-inflammatory agent 45
  • HY-160246
    QL47B

    		Btk Cancer
    QL47B, a biotinylated analogue of QL47 (HY-80003), is a potent inhibitor of BTK, with an IC50 value of 1.3 μM. QL47B has anti-tumor activity .
    QL47B
  • HY-160245
    QL47R

    		Btk Others
    QL47R is an approximately isosteric analogue of QL47 (HY-80003). QL47R dose not inhibit the biochemical kinase activity of BTK at concentrations below 10 μM. QL47R dose not display antiproliferative activity on B-Cell Lymphoma Cell Lines at concentrations of less than 10 μM .
    QL47R
  • HY-W784565
    5-Fluorouridine 5'-phosphate

    		DNA/RNA Synthesis Cancer
    5-Fluorouridine 5'-phosphate is an ODCase (orotidine-5′-monophosphate decarboxylase) inhibitor, with a Ki value of 98 µM for human ODCase and a Ki value of 645 µM for Methanobacterium ODCase. 5-Fluorouridine 5'-phosphate exhibits inhibitory activity against leukemia and lymphoma cell lines and can be used in cancer research .
    5-Fluorouridine 5'-phosphate
  • HY-P991555
    XmAb5485

    		TNF Receptor Apoptosis Cancer
    XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .
    XmAb5485
  • HY-144791
    Bcl-2-IN-6

    		Bcl-2 Family MDM-2/p53 Caspase Apoptosis Cancer
    Bcl-2-IN-6 (compound 10) is a potent Bcl-2 (B-cell lymphoma-2) inhibitor. Bcl-2-IN-7 down-regulates the expression of Bcl-2, and increases the expression of p53, Bax, and caspase-7 mRNA. Bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. Bcl-2-IN-7 shows good anticancer activity, with IC50 values of 20.91, 22.30, 42.29, and 48.00 μM against MCF-7, LoVo, HepG2, and A549 cell lines, respectively .
    Bcl-2-IN-6
  • HY-144792
    Bcl-2-IN-7

    		Bcl-2 Family MDM-2/p53 Caspase Apoptosis Cancer
    Bcl-2-IN-7 (compound 6) is a potent Bcl-2 (B-cell lymphoma-2) inhibitor. Bcl-2-IN-7 down-regulates the expression of Bcl-2, and increases the expression of p53, Bax, and caspase-7 mRNA. Bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. Bcl-2-IN-7 shows good anticancer activity, with IC50 values of 20.17, 22.64, 45.57, and 51.50 μM against MCF-7, LoVo, HepG2, and A549 cell lines, respectively .
    Bcl-2-IN-7
  • HY-128910
    MC-VC(S)-PABQ-Tubulysin M

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    MC-VC(S)-PABQ-Tubulysin M is a synthetic ADC drug-linker conjugate composed of the tubulin polymerization inhibitor Tubulysin M (an ADC Cytotoxin) (HY-N7053) and MC-VC(S)- PABQ (an ADC linker) is connected. MC-VC(S)-PABQ-Tubulysin M is effective against multidrug-resistant lymphoma cell lines and tumors .
    MC-VC(S)-PABQ-Tubulysin M
  • HY-169684
    Vaccarin C

    		Fungal Infection Cancer
    Vaccarin C (Compound VIII) is a cycloheptapeptide with good antifungal activity against pathogenic fungi and dermatophytes M. audouinii and T. mentagrophytes with MIC values of 6 µg/mL. Vaccarin C also has high cytotoxicity against Dalton's lymphoma ascites (DLA) and Ehrlich's ascites carcinoma (EAC) cell lines with IC50 values of 3.35 and 5.72 μM, respectively .
    Vaccarin C
  • HY-117622
    ND-2110

    		IRAK Inflammation/Immunology Cancer
    ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models .
    ND-2110
  • HY-149726
    EZH2-IN-17

    		Histone Methyltransferase Cancer
    EZH2-IN-17 (compound 28) is a potent and orally active EZH2 inhibitor with an IC50 value of 0.95 nM. EZH2-IN-17 exhibits high anti-proliferation activity against different lymphoma cell lines including WSU-DLCL2, Pfeiffer and Karpas-422 (IC50 values of 2.36 nM, 1.73 nM, and 1.82 nM, respectively) .
    EZH2-IN-17
  • HY-117540
    ZLD10A

    		Histone Methyltransferase Cancer
    ZLD10A is a highly potent and selective EZH2 inhibitor with the activity of inhibiting H3K27 methylation. ZLD10A can inhibit wild-type and mutant EZH2 with nanomolar potency and has more than 1000-fold selectivity for the other 10 histone methyltransferases. ZLD10A inhibited cell proliferation of DLBCL cell lines in a concentration- and time-dependent manner, showing a potential antiproliferative effect. ZLD10A can be used in the study of EZH2 mutant lymphomas .
    ZLD10A
  • HY-15191B
    (S)-Sabutoclax

    (S)-BI-97C1

    		 Bcl-2 Family Cancer
    (S)-Sabutoclax ((S)-BI-97C1), an optically pure apogossypol derivative, is pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. (S)-Sabutoclax (Compound II) inhibits the binding of BH3 peptides to Bcl-XL, Bcl-2, Mcl-1, and Bfl-1 with IC50 values of 0.31, 0.32, 0.20, and 0.62 μM, respectively. (S)-Sabutoclax also potently inhibits cell growth of human prostate cancer, lung cancer, and lymphoma cell lines with EC50 values of 0.13, 0.56, and 0.049 μM, respectively. (S)-Sabutoclax can be used for the research of apoptosis-based therapies against cancer .
    (S)-Sabutoclax
  • HY-176165
    CDK9/EZH2-IN-1

    		CDK Histone Methyltransferase Cancer
    CDK9/EZH2-IN-1 (Compound D16) is a CDK9/EZH2 dual-target inhibitor (IC50: 83.9/108.6 nM). CDK9/EZH2-IN-1 induces apoptosis and DNA double-strand breaks (DSBs). CDK9/EZH2-IN-1 inhibits the proliferation activity of MKN45, MDA-MB-453 and SW620 cancer cells (IC50 values are 136.3, 171.3 and 315.7 nM, respectively) .
    CDK9/EZH2-IN-1
  • HY-175002
    PI3Kδ-IN-24

    		PI3K Akt Apoptosis Cancer
    PI3Kδ-IN-24 is a selective PI3Kδ inhibitor (IC50 = 0.1 nM). PI3Kδ-IN-24 exhibits significant antiproliferative effects against PI3Kδ-overexpressing cancer cell lines. PI3Kδ-IN-24 reduces p-AKT levels and induces cell cycle arrest and apoptosis in tumor cells. PI3Kδ-IN-24 is useful in cancer research, such as diffuse large B-cell lymphoma (DLBCL) .
    PI3Kδ-IN-24
  • HY-141599
    Camidanlumab tesirine

    ADCT 301

    		 Antibody-Drug Conjugates (ADCs) Interleukin Related Cancer
    Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .
    Camidanlumab tesirine
  • HY-115944
    BTK-IN-9

    		Btk Apoptosis Inflammation/Immunology Cancer
    BTK-IN-9 is a reversible BTK inhibitors with potent antiproliferative activity in mantle cell lymphoma. BTK-IN-9 specifically disturbs mitochondrial membrane potential and increases reactive oxygen species level in Z138 cells. BTK-IN-9 also induces cell apoptosis in Z138 cells .
    BTK-IN-9
  • HY-176701
    PRMT5-MTA-IN-4

    		Histone Methyltransferase Cancer
    PRMT5-MTA-IN-4 (Compound 30) is a potent irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50=8 nM). PRMT5-MTA-IN-4 blocks arginine methylation, inhibiting ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-4 exhibits antiproliferative activity in multiple tumor cell lines (e.g., IC50=0.3 μM in DLD-1 cells). PRMT5-MTA-IN-4 is promising for research of hematological malignancies, such as acute myeloid leukemia, diffuse large B-cell lymphoma .
    PRMT5-MTA-IN-4
  • HY-N14774
    Lactoquinomycin B

    		Antibiotic Bacterial Infection
    Lactoquinomycin B is a quinone antibiotic. Lactoquinomycin B has the activity of anti-Gram-positive bacteria and some Gram-negative bacteria, but the effect of anti-Gram-negative bacteria is weak and has no effect on fungi. Lactoquinomycin B inhibits a variety of cell lines including lymphoma L5178Y progenitor, Adriamycin resistant, Bleomycin-resistant, human leukemia K562, mouse leukemia L-1210 and mouse leukemia P 388 with ID50 (μg/mL) of 0.43, 0.21, 0.19, 0.16, 0.2 and 0.12, respectively .
    Lactoquinomycin B
  • HY-117285
    Medermycin

    Lactoquinomycin A; LQM-A

    		 Antibiotic Bacterial Infection Cancer
    Lactoquinomycin A is a quinone antibiotic. Lactoquinomycin A has the activity of anti-Gram-positive bacteria and some Gram-negative bacteria, but the effect of anti-Gram-negative bacteria is weak and has no effect on fungi. Lactoquinomycin A inhibits a variety of cell lines including lymphoma L5178Y progenitor, Adriamycin resistant, Bleomycin-resistant, human leukemia K562, mouse leukemia L-1210 and mouse leukemia P 388 with ID50 (μg/mL) of 0.02, 0.006, 0.008, 0.033, 0.013 and 0.03, respectively .
    Medermycin
  • HY-156292
    IHMT-EZH2-426

    		Histone Methyltransferase Cancer
    IHMT-EZH2-426 (compound 38) is an effective covalent EZH2 degrader, with IC50 values of 1.3 nM, 1.2 nM, and 1.7-3.5 nM for EZH2 wild type, EZH2-A687V, and EZH2-Y641F/Y641N/Y641S, respectively. IHMT-EZH2-426 reduces H3K27me3 and EZH2 levels and shows effective anti-proliferative effects in B-cell lymphoma and TNBC cell lines.
    IHMT-EZH2-426
  • HY-172889
    PI3K/HDAC-IN-4

    		PI3K HDAC Apoptosis mTOR Akt Cancer
    PI3K/HDAC-IN-4 (Compound 31f) is a PI3K/HDAC dual inhibitor (IC50: 0.2μM). PI3K/HDAC-IN-4 shows high selectivity for HDAC1-3 (IC50 values of 75.5 nM, 70.9 nM, and 1.9 nM, respectively). PI3K/HDAC-IN-4 is a potent PIK3 inhibitor with IC50 values of 2.5 nM, 80.5 nM, 10.0 nM, and 57.2 nM for PI3Kα, β, δ, and γ, respectively. PI3K/HDAC-IN-4 significantly induces tumor cell apoptosis by simultaneously inhibiting the PI3K/AKT/mTOR signaling pathway and HDAC1-3. PI3K/HDAC-IN-4 exhibits potent antiproliferative activity in a variety of tumor cell lines (e.g., MV4-11, Jeko-1, HL60, and MCF-7, with IC50 values of 0.2, 0.9, 0.8, and 1.5 μM, respectively). PI3K/HDAC-IN-4 can be used in the study of lymphoma and leukemia .
    PI3K/HDAC-IN-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: